Radiation boost may extend immunotherapy benefits in advanced liver cancer

NCT ID NCT06434480

Recruiting now Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Mar 05, 2026 · Last updated May 08, 2026 · Updated 5 times

Summary

This study tests whether adding targeted radiation (SBRT) to spots where liver cancer has started growing again can help patients continue benefiting from immunotherapy. About 30 adults with advanced liver cancer that has progressed in a few places while on first-line immunotherapy will receive SBRT to those spots. The goal is to see if this approach can delay further cancer growth and improve survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of Clinical Oncology, Prince of Wales Hospital
RECRUITING

Hong Kong, Hong Kong

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HCC